Pages that link to "Q71050602"
Jump to navigation
Jump to search
The following pages link to Howard L. Kaufman (Q71050602):
Displaying 50 items.
- Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. (Q27323196) (← links)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (Q28553703) (← links)
- Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses (Q33606166) (← links)
- Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules (Q33637231) (← links)
- Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. (Q33774512) (← links)
- Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma (Q33840446) (← links)
- gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma (Q34188859) (← links)
- Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy (Q34606479) (← links)
- Immunotherapy for pancreatic cancer: current concepts (Q34684162) (← links)
- Chemokines and cancer. (Q34798754) (← links)
- Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide (Q34827708) (← links)
- An update on TroVax for the treatment of progressive castration-resistant prostate cancer (Q35050205) (← links)
- Poxviruses as vectors for cancer immunotherapy. (Q35096361) (← links)
- The contralateral sentinel node. (Q35538035) (← links)
- Surgical treatment of stage IV melanoma. (Q35840506) (← links)
- Gene therapy with poxvirus vectors. (Q36240465) (← links)
- Pox viral vaccine approaches. (Q36336369) (← links)
- Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer (Q36412657) (← links)
- A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer (Q36421822) (← links)
- The tumour microenvironment and implications for cancer immunotherapy (Q36521830) (← links)
- Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (Q37074226) (← links)
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma (Q37267697) (← links)
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy (Q37267785) (← links)
- Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma (Q37399308) (← links)
- Mutant HSP70 reverses autoimmune depigmentation in vitiligo (Q37551330) (← links)
- Discovery and clinical introduction of first-in-class imipridone ONC201. (Q37687570) (← links)
- TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development (Q37803061) (← links)
- TroVax(®) vaccine therapy for renal cell carcinoma (Q37965748) (← links)
- Vaccines for melanoma and renal cell carcinoma. (Q38010831) (← links)
- Oncolytic virus immunotherapy for melanoma (Q38380394) (← links)
- Oncolytic viruses: a new class of immunotherapy drugs (Q38577450) (← links)
- Surgical Management of Melanoma (Q38646103) (← links)
- Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy (Q38683730) (← links)
- Intratumoral Approaches for the Treatment of Melanoma (Q38766807) (← links)
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma (Q38781322) (← links)
- IFN-λ cancer immunotherapy: new kid on the block (Q38887297) (← links)
- Oncolytic virus therapy for cancer (Q38924529) (← links)
- Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma (Q38924543) (← links)
- HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice (Q39018737) (← links)
- Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment (Q39503772) (← links)
- MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. (Q39774023) (← links)
- OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma (Q39866378) (← links)
- Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. (Q40498026) (← links)
- NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. (Q40852288) (← links)
- High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis (Q42971742) (← links)
- Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". (Q43127268) (← links)
- Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer (Q45388589) (← links)
- Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors (Q45420180) (← links)
- Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles (Q45590933) (← links)
- Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand (Q45618074) (← links)